score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S880F	0.4169	343.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0	0.0	0.0	0.0	PDGFRA p.S880F (Missense)	0.0	MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	MEL-IPI_Pat33-Normal-SM-4NFUZ
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E996K	0.4514	257.0	8e-06	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0	0.0	0.0	0.0	PDGFRA p.E996K (Missense)	0.0	MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	MEL-IPI_Pat33-Normal-SM-4NFUZ
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat33		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat33		
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.D635N	0.3962	159.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0	0.0	0.0	0.0	TSC2 p.D635N (Missense)		MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	MEL-IPI_Pat33-Normal-SM-4NFUZ
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32N	0.3805	205.0	0.0	0.0																Investigate Actionability	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0	0.0	0.0	0.0	CTNNB1 p.D32N (Missense)		MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	MEL-IPI_Pat33-Normal-SM-4NFUZ
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E470*	0.2171	175.0	0.0	0.0																					0	0.0	0.0	0.0	NF1 p.E470* (Nonsense)		MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	MEL-IPI_Pat33-Normal-SM-4NFUZ
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R1362*	0.5802	424.0	8e-06	0.0																					0	0.0	0.0	0.0	NF1 p.R1362* (Nonsense)		MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	MEL-IPI_Pat33-Normal-SM-4NFUZ
Biologically Relevant				Copy Number	COL1A1	Amplification				0.0	0.0																					0				COL1A1 Amplification		MEL-IPI_Pat33	MEL-IPI_Pat33-Tumor-SM-4DK1T	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat33		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.739																									0				COSMIC Signature (version 2) 7 (74%)		MEL-IPI_Pat33		
